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Abstract
Fungi in the genus Pneumocystis cause pneumonia (PCP) in hosts with debilitated immune systems and are emerging as co-
morbidity factors associated with chronic diseases such as COPD. Limited therapeutic choices and poor understanding of
the life cycle are a result of the inability of these fungi to grow outside the mammalian lung. Within the alveolar lumen,
Pneumocystis spp., appear to have a bi-phasic life cycle consisting of an asexual phase characterized by binary fission of
trophic forms and a sexual cycle resulting in formation of cysts, but the life cycle stage that transmits the infection is not
known. The cysts, but not the trophic forms, express b -1,3-D-glucan synthetase and contain abundant b -1,3-D-glucan. Here
we show that therapeutic and prophylactic treatment of PCP with echinocandins, compounds which inhibit the synthesis of
b -1,3-D-glucan, depleted cysts in rodent models of PCP, while sparing the trophic forms which remained in significant
numbers. Survival was enhanced in the echincandin treated mice, likely due to the decreased b -1,3-D-glucan content in the
lungs of treated mice and rats which coincided with reductions of cyst numbers, and dramatic remodeling of organism
morphology. Strong evidence for the cyst as the agent of transmission was provided by the failure of anidulafungin-treated
mice to transmit the infection. We show for the first time that withdrawal of anidulafungin treatment with continued
immunosuppression permitted the repopulation of cyst forms. Treatment of PCP with an echinocandin alone will not likely
result in eradication of infection and cessation of echinocandin treatment while the patient remains immunosuppressed
could result in relapse. Importantly, the echinocandins provide novel and powerful chemical tools to probe the still poorly
understood bi-phasic life cycle of this genus of fungal pathogens.
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Introduction
Pneumocystis spp. are yeast-like fungi that reside extracellularly in
lung alveoli and can cause a lethal pneumonia (PCP) in
mammalian hosts with debilitated immune systems. Microscopic
observations and molecular genetic studies suggest a life cycle that
contains an asexual mode of replication via binary fission of the
trophic form and a sexual mode resulting in formation of an ascus
(cyst) containing 8 ascospores [1,2]. Budding has not been
observed in this genus. Mating is likely mediated by the trophic
forms, as evidenced by several mating associated yeast homologs
present in the P. carinii genome [3] and the expression of a
pheromone receptor protein on the surface of the trophs [4]. The
infection is thought to be initiated by attachment of the trophic
forms to the Type I pneumocyte in the host alveoli. However, the
mode of travel by the trophs to the alveoli is unknown, nor has the
actual infectious propagule been identified. Transmission from one
host to another is thought to be via an airborne route, but there is
some evidence supporting alternative transmission through direct
contact [5]. No environmental form or cycle has been identified.
Although the incidence of P. jirovecii Pneumonia (PCP) has
decreased in industrialized countries with the introduction of
Highly Active Anti-Retroviral Therapy (HAART) in 1996, PCP
remains the leading opportunistic infection among HIV-infected
patients and a serious clinical problem [6]. The mortality rate
associated with PCP prior to and after the era of HAART has not
changed significantly in the United States from an average of 10–
15% [6,7]. In developing countries and within urban areas of the
United States, mortality is much higher, despite the availability of
HAART [8]. The recent detection of Pneumocystis jirovecii in new
patient populations such as those with chronic diseases states like
chronic obstructive pulmonary disorder (COPD) [9,10] or in those
receiving anti-TNF therapy and other immunosuppressive agents
[11,12] demands a better understanding of the kinetics of its bi-
phasic life cycle and the role each plays in establishment of
infection, persistence, transmission, and pathology.
Standard antifungal drugs targeting ergosterol and ergosterol
biosynthesis such as amphotericin B and the azoles, are ineffective
against PCP [13]. The primary therapy for PCP is the
combination of the anti-folate inhibitors trimethoprim-sulfameth-
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However, there are significant prophylactic breakthroughs and
treatment failures associated with this combination, and second
line therapies such as clindamycin-primaquine, atovaquone, or
pentamidine have high rates of relapse and recurrence [14,15].
Pentamidine and TMP-SMX both have significant side effects
including nephrotoxicity and in the case of TMP-SMX, severe
rash, fever, and neutropenia that often necessitate a change to
alternative therapy. Long-term in vitro propagation of Pneumocystis
spp. is not possible and the development of potential new therapies
has necessarily been conducted using rodent models of infection.
Because of the limited alternative anti-PCP therapies, physicians
have resorted to using salvage therapies such as the echinocandins.
Echinocandins are a relatively new family of anti-fungal
compounds that exhibit fungicidal activity against Candida species,
including triazole-resistant isolates, and fungistatic activity against
Aspergillus species [16]. Echinocandins inhibit synthesis of b -1,3-D-
glucan, an essential component of the cell wall of many fungi,
including the cyst form of Pneumocystis spp., not present in
mammalian cells.
Reports of the efficacy of the echinocandins on PCP in patients
have been contradictory [17,18,19,20,21]. This is due to the
anecdotal nature of the reports, the low numbers of patients
receiving treatment, and the use of the echinocandin as salvage
therapy concomitant with other treatment. Except for studies
performed in the 1990s which focused on caspofungin and FK463,
(later called micafungin) [22], there have been no other studies of
these compounds in animal models of Pneumocystis spp. [23,24]. In
the caspofungin studies (23), it was proposed that the cyst stage was
required for ‘trophozoite’’ proliferation, but this was not tested
directly. In addition, the question of whether the cysts or infection
could return after stopping therapy was never addressed.
Because of the potential clinical use of the currently available
echinocandins: anidulafungin, caspofungin and micafungin, and to
address questions regarding effects on the life cycle and transmission
of Pneumocystis spp., we conducted the first systematic evaluationof b
-1,3-D-glucan synthase inhibitors in the mouse model of PCP with
verification in the rat model. We tested the hypothesis that the cyst
cycle was necessary for completion of the life cycle; whether it was
the agent of transmission for Pneumocystis pneumonia; and if the
echinocandin treatment would block repopulation of the cysts after
treatment cessation. The consequences of these compounds on
survival, organism morphology, and b-1,3-D-glucan content in the
infected mouse lung were evaluated to provide a comprehensive
picture of their myriad of effects on Pneumocystis.
Results
Therapy with the Echinocandins Targets the Cyst Form
Therapeutic treatment with anidulafungin, caspofungin and
micafungin, administered 3 times per week for 3 weeks
significantly reduced cyst burdens by 2 logs or more vs
untreated mice (C/S; Control, Steroids) at doses of 10- to
2.5 mg/kg, (Figure 1a). With the exception of 10 mg/kg
Figure 1. Therapeutic effects of anidulafungin, caspofungin and micafungin on P. murina cysts and trophic forms. Data in all panels
represents mice treated 3 times per week for 3 weeks with anidulafungin (green bars), caspofungin (yellow bars), micafungin (blue bars) at the doses
noted and trimethoprim-sulfamethoxazole at 50/200 mg/kg (pink bars, T/S) or untreated (red bars, C/S). Bars indicate log10 mean cysts6standard
deviation (SD) per lung. Panel A: High dose echinocandin treatment, cyst burdens. All groups were significantly different than the untreated control
mice (C/S), P,0.001. Panel B: Low dose echinocandin treatment, cyst burdens. Cyst burdens were compared to untreated controls (C/S) and P values
for each group are listed on the graph; (*) indicates P,0.001. Panel C: High dose echinocandin treatment, trophic burdens *P,0.001 treated vs
untreated control mice (C/S). Panel D: Low dose echinocandin treatment, trophic burdens. *P,0.001 treated vs untreated control mice.
doi:10.1371/journal.pone.0008524.g001
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not significantly different than TMP-SMX (T/S), nor did they
differ in efficacy from one another. At all of the lower doses (1.0-
to 0.1 mg/kg), anidulafungin and caspofungin significantly
reduced cyst burdens, while micafungin reduced cysts only at
1 mg/kg (Figure 1b). No dose response was observed for any
echinocandin.
In contrast to the dramatic reductions of cysts, large numbers of
trophic forms remained in the lungs of treated mice, often
reaching levels that were not significantly different than untreated
controls (Figure 1c,d.). Micafungin was the least effective with no
significant reduction in trophic burden at any dose vs untreated
control mice (C/S). The overall reductions were modest with a
range from 1.1 log (10 mg/kg caspofungin) to 2 logs (2.5 mg/kg
caspofungin). In contrast, TMP-SMX reduced the log10 P. murina
nuclear count to undetectable levels. At the lower doses (Figure 1d),
only caspofungin at 1 mg/kg and anidulafungin at 0.5 mg/kg
were able to significantly reduce the trophic burdens as compared
to the untreated mice. There was no dose response within any
echinocandin series.
Survival Is Enhanced by Echinocandin Treatment
Despite large trophic burdens, many of the treated mice had
enhanced survival as compared to untreated mice (Figure 2). At
the 10 mg/kg dose, all 3 echinocandins showed increased survival.
Notably, anidulafungin treatment at each of the 6 doses provided
significantly increased survival, while mice treated with caspofun-
gin at doses of 1.0 mg/kg and 0.5 mg/kg only afforded increased
survival rates. The survival rates were not associated with
reductions in trophic burdens. For example, treatment with
caspofungin at 2.5 mg/kg markedly reduced both cyst and trophic
burdens, but did not increase survival as compared to untreated
controls.
Dramatic Morphological Remodeling
Similar to the effects on Aspergillus fumigatus [25], P. murina
underwent profound morphological changes as a result of
echinocandin treatment (Figure 3.). The silver impregnation of
the P. murina in the lungs of the treated mice was noticeably
diminished in the GMS (Grocott’s methenamine silver) stained
slides (Panels d-l) while those from the untreated mice exhibited
strong silver staining and typical cup-shaped cyst morphology
(Panels a–c). This was especially apparent in the mice treated with
10 mg/kg of any of the echinocandins (Panels d, g, j), where the
organism infiltrates were characterized by diffuse staining without
clearly circumscribed boundaries and the lack of cysts. Many of
the organisms in 10- and 5 mg/ml dose treatments formed stacked
coalescent structures on the alveolar epithelial cells suggestive of
biofilms (See Panel g, for example). A prominent characteristic was
the appearance of numerous GMS-staining bodies within the
masses of the treated P. murina. These bodies showed great
variation in size and shape and often appeared ‘‘fragmented’’ in a
manner reminiscent of karyorrhexis in nucleated mammalian cells.
Shown in Panel l (arrow) is an example of an enlarged cyst- like
structure with just a single GMS-staining body. Distinct morphol-
ogies were observed in micafungin treated organisms. As shown in
Panel h (5 mg/ml), P. murina from these mice often formed
elongated structures reminiscent of abberrant hyphae. In mice
treated with 1 mg/ml micafungin, cysts with typical morphologies
were apparent (Panel i, arrow), which coincided with the reduced
efficacy at this dose. Organisms from mice treated with
caspofungin and anidulafungin, also exhibited unusual morphol-
ogies (Figure S1).
Cysts Repopulate the Lungs after Cessation of
Echinocandin Therapy
To address the question of whether cysts would repopulate the
lungs of echinocandin- treated immunosuppressed mice after
therapy was stopped, 2 studies were performed using only
anidulafungin (1 mg/kg). No cyst forms were detected in the
lungs of the mice that were examined immediately after stopping
treatment, as expected (Figure 4a). Following withdrawal of the
anidulafungin, cysts gradually repopulated the lungs over time
(Figure 4a). After 2 weeks, significantly more cysts were detected
compared to the 0 time point. By 4 weeks, cyst numbers reached
the same level as untreated mice. Similar numbers of trophic forms
were detected in all of the groups (Fig 4b).
Verification of Cyst Targeting in the Rat Model of PCP
As in the mouse model, there was a marked decrease in cysts in
the treated rats while trophic form numbers were similar to those
from untreated rats. Untreated, steroid immunosuppressed rats
had an average P. carinii log10 cyst count of 8.3861.01 SD while
the anidulafungin- treated rats had average cyst counts of
5.8960.82 SD (P,0.01). The average P. carinii log10 trophs in
the untreated, steroid immunosuppressed rats was 8.5661.14 SD
vs 7.3860.69 SD in the anidulafungin treated group (P.0.05).
Prophylaxis Resulted in Diminished Infections
Prophylactic treatment with low dose anidulafungin and
caspofungin resulted in infections with diminished numbers of P.
murina, but not complete inhibition. Treatment with either
echinocandin at 1 mg/kg or 0.1 mg/kg given 3 times a week or
once per week reduced cysts significantly when compared to the
untreated controls (Figure 5a). Elevated cyst numbers were
observed at 0.1 mg/kg administered only once per week for each
compound, but even at these doses the cysts were significantly
decreased vs untreated control mice. There were no statistical
differences between the thrice weekly vs once weekly dosing at
1 mg/kg for either anidulafungin or caspofungin, but caspofungin
and anidulafungin at 0.1 mg/kg, administered three times per
week, were more efficacious in reducing cyst burdens than
anidulafungin at the same dose given once per week (P,0.001).
Caspofungin at 0.1 mg/kg once per week was also more effective
than anidulafungin at the same dose schedule (P,0.001). At the
lower concentration of TMP/SMX used for prophylaxis, cysts
were significantly reduced vs. untreated control; however, at this
low dosage, cyst burdens in mice treated with caspofungin and
anidulafungin were significantly lower than those treated with
TMP/SMX in all of the regimens (P,0.01).
As observed in the therapeutic studies, trophic forms in the
prophylactically treated mice were more refractive to the
echinocandins than cysts (Figure 5b), but mice treated with any
of the prophylactic regimens had trophic burdens significantly
lower than untreated mice. The ability of prophylactic adminis-
tration to inhibit a robust infection suggests that blocking of b- 1,3-
D-glucan synthesis interfered with establishment of a fulminate
infection by inhibiting cyst formation in the recipient mice. Low
doses of the echinocandins may have permitted some cysts to
excyst in the treated mouse lungs and establish asexual, trophic
replication but without the ability to enter the cyst cycle, were
impeded in their ability to establish robust infection.
Survival in the prophylactically treated groups was generally
enhanced when compared to the untreated mice. When
administered 3 times per week all mice survived in both of the
1.0- and 0.1 mg/kg caspofungin groups as compared to 42% in
the untreated group (Figure 5d). Although the other treatment
Echinocandin Treatment of PCP
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point (67–83%), these data did not reach statistical significance.
When administered once per week, only the group that received
1.0 mg/kg anidulafungin had a statistically significant better
survival rate than untreated mice (Figure 5c). However, as in the
thrice weekly schedule, the majority ($75%) of mice survived in all
the treatment groups.
The b-1,3-D-Glucan Content Was Decreased in
Echinocandin-Treated Rodent Lungs
The b-1,3-D-glucan content was measured in the lungs of the
prophylactically treated mouse groups (shown in Fig. 5.) and
the therapeutically treated rat groups (discussed above). As
expected, the loss of cysts in the echinocandin-treated animals
correlated with a reduction of b-1,3-D-glucan content (Fig. 6).
The same 3 groups of mice that had elevated cyst numbers
apparent in Fig. 5a also had dramatically higher b-1,3-D-
glucan content (untreated control mice, mice treated with
0.1 mg/kg/1x/wk anidulafungin or low-dose TMP-SMX),
shown in Fig. 6. In rats treated therapeutically with anidula-
fungin, the b-1,3-D-glucan content was significantly different
from the untreated rat lungs, as were the cyst counts (857.4 pg/
ml6611.3 SD in the untreated group and 90.6 pg/
ml6134.3 S.D. in the anidulafungin treated group). These
data show that the loss of cysts was proportional to the decrease
in b-1,3-D-glucan content.
Figure 2. Survival curves of mice treated therapeutically with anidulafungin, caspofungin, micafungin. Percent survival for treated vs
untreated mice was calculated for the 21 day treatment period using GraphPad Prism v.4. Asterisks indicate a significant difference from untreated
controls (C/S). Line colors reflect the treatment and regimen as shown on the figure legend. Panel A: 10 mg/kg treatment regimen: anidulafungin:
P=0.02; caspofungin: P=0.006; micafungin: P=0.0006; T/S: 0.002. Panel B: 5 mg/kg treatment regimen: anidulafungin: P=0.002; T/S: P=0.02; Panel
C: 2.5 mg/kg regimen: anidulafungin: P=0.004; T/S: P=0.002; Panel D: 1.0 mg/kg regimen: anidulafungin: P=0.0049; caspofungin: P=0.002; T/S:
P=0.002; Panel E: 0.5 mg/kg regimen: anidulafungin: P=0.002; caspofungin:P=0.007; T/S: P=0.002; Panel F: 0.1 mg/kg regimen: anidulafungin:
P=0.004; T/S: P=0.002.
doi:10.1371/journal.pone.0008524.g002
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Staining with a mAB Directed to b-1,3-D-Glucan
Fluorescent staining with a mAb specific for b-1,3-D-glucan was
used to verify its presence in cysts and not in trophs; to evaluate the
staining pattern of cysts; and to assess whether treatment with
anidulafungin would lead to an ‘‘unmasking’’ of the b-1,3-D-
glucan as reported for C. albicans [26,27] and A. fumigatus [28,29].
As expected, trophic forms did not stain while cysts emitted a
robust fluorescence that appeared to be localized to the surface
and in discrete round particles in untreated P. carinii (Figure 7a,b).
Following treatment of P. carinii cysts with anidulafungin for
24 hours, no change in fluorescent intensity was apparent when
evaluated by microscopic methods (Figure 7c,d) or by quantitiative
measurement of fluorescent intensity (58,877 Fluorescent intensity
units (FIU)6903 S.D. for the untreated control group vs.
47,834 FIU65,647 for the anidulafungin-treated group, two-
tailed P=0.19).
Evidence for the Cyst as the Agent of Transmission
Anidulafungin was used as a chemical tool to interrogate the
role of the cyst or trophic form as the agent of transmission.
Results of these experiments demonstrated that anidulafungin
treatment significantly reduced the ability of mice to transmit the
infection by the seeding method, the most natural form of
propagation of PCP (Figure 8a). No cyst forms were detected at
any of the time points in recipient mice seeded with anidulafungin
treated seed mice by microscopic evaluation (Anid Tx 2, 4, 6).
[Note log 4.24 is the level of sensitivity of microscopic evaluation; a value of
Figure 3. Histological morphology of P. murina treated with caspofungin, micafungin and anidulafungin. Grocott’s methenamine silver-
stained sections of lungs from: untreated mice (Panels A–C); representative sections from mice treated with 10-, 5- and 1 mg/kg caspofungin (Panels
D–F;) representative sections from mice treated with 10-, 5- and 1 mg/kg micafungin (Panels G–I); and 10-, 5- and 1 mg/kg anidulafungin (Panels J–L).
1,2506magnification; 10 um bars in Panels A–C are the same for Panels D–L. Arrows indicate morphologies discussed in the text.
doi:10.1371/journal.pone.0008524.g003
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mice that were seeded with control, immunosuppressed but
untreated mice (Not Tx 2, 4, 6), no cyst forms were detected after
2 wk time of immunosuppression; but log10 mean cyst counts per
lung of approximately 5.0 and 6.0 were detected in the 4 and 6 wk
groups (Fig. 8a, blue, green bars). No cyst forms were detected in
any of the non-exposed immunosuppressed control mice (Cont 2,
4, 6).
To determine whether the anidulafungin treated mice possibly
transmitted the infection at low levels, (below the limit of
microscopic detection) the recipient mice were evaluated for the
presence of P. murina by RT-qPCR analysis. The results of this
analysis confirmed the findings of the microscopic evaluation
(Fig. 8b.). Either no or very low levels (,1 P. murina nuclei/rx) of P.
murina mtLSU message was detected by RT-qPCR analysis in the
lungs of recipient mice that were seeded with mice that were
treated with anidulafungin (‘‘Anid’’) at 2, 4, and 6 weeks post
exposure. In mice that were seeded with the non-treated and
infected control mice, mtLSU message was detected in all mice at
all 3 time points in the lungs of exposed mice (Fig. 8b, Not Tx 2-,
4- and 6). At the 6 week time point, significantly higher levels
mtLSU were detected in the mice seeded with untreated infected
mice compared to mice seeded with treated mice (P,0.01). No
mtLSU message was detected in any of the unexposed
immunosuppressed control mice (Cont 2, 4, 6).
Trophic Forms Remaining after Anidulafungin Treatment
Are Viable and Infective
To evaluate whether the trophic populations isolated from
anidulafungin treated mice were viable and infective, P. murina
isolated from either the treated or non-treated control seed mice,
were used to infect P. murina-naı ¨ve immunosuppressed mice by
intranasal instillation of 10
7nuclei. The mice were sacrificed at 2,
4, and 6 weeks post inoculation and evaluated for P. murina
infection by RT-qPCR and microscopic enumeration, as de-
scribed above.
No cysts were detected microscopically at 2 wks in mice that
were inoculated with control or treated P. murina (Fig. 9a, Anid Tx
2, Not Tx 2). At 4 and 6 wks, log10 mean cyst counts of
approximately 4.7 and 6.0 were detected in the groups of mice
infected with anidulafungin-treated P. murina (Fig. 9a, Anid Tx 4
and Anid Tx 6). However, significantly higher numbers of cyst
forms were detected in mice that were infected with P. murina from
non-treated mice at these same time points (Not Tx 4, 6) (P,0.05).
These mice had log mean cyst counts of approximately 6.0 and 7.0
per group at the same time points (Fig. 9a). No cyst forms were
detected in control mice that were immunosuppressed and
uninoculated (Cont 2,4,6).
By Reverse Transcriptase qPCR analysis (which also served as a
viability assessment), an average of approximately 1, 48, and 1000
nuclei per rx (reaction) were detected in groups of mice at the 2, 4,
and 6 wk time points in mice infected with treated P. murina
(Fig. 9b, Anid Tx 2, Anid Tx 4, Anid Tx 6). In mice that received
non-treated P. murina, an average of approximately 20, 200 and
6000 nuclei/rx were detected per group at the same time points
(Fig. 9b, Not Tx 2, Not Tx 4, Not Tx 6). No mtLSU message was
detected in any of the unexposed immunosuppressed control mice
(Cont 2, 4, 6).
Discussion
There are both significant clinical and biological implications of
these studies. In regard to clinical significance, the results
presented here show for the first time that there is a hierarchy
of efficacy against PCP among the echinocandins. Caspofungin
and anidulafungin were significantly better at reducing cyst
burdens than micafungin. However, unlike treatment of C. albicans
infections with caspofungin which results in a candicidal effect,
treatment of Pneumocystis spp. with these compounds targeted the
cysts, sparing the trophic forms and was not pneumocidal. This
selectivity is more similar to the effects of echinocandins on
Aspergillus fumigatus, which do not fully inhibit its growth and target
the hyphal stage [25].
Our results strongly suggest that micafungin would not be a
suitable choice for clinical use and any echinocandin treatment
should not be administered as a mono-therapy, as the infection is
not eradicated. The withdrawal of anidulafungin treatment and
subsequent cyst repopulation also pose a cautionary note for the
clinical use of echinocandins to treat Pneumocystis jirovecii pneumo-
nia, as cessation of therapy could result in relapse. However,
administration of an echinocandin in combination with TMP-
SMX (or other therapy) could provide significant benefits by
decreasing the inflammatory responses associated with b-1,3-
Figure 4. Cysts return after withdrawal of anidulafungin. (Panel A) Average log cyst counts. Week 2 vs 0 wk. (*) P,0.05; Weeks 4, 6 vs 0 wk
(**) P,0.001 (Panel B) Average log trophic counts. No significant differences among the groups when compared to time point ‘‘0’’. Weeks 2 and 4
post treatment were significantly different (P,0.05). The biological significance of this difference is unknown.
doi:10.1371/journal.pone.0008524.g004
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faster acting than TMP-SMX. It is possible these effects would
lead to lower mortality rates as well. Administration of
echinocandins may be particularly useful during immune
reconstitution syndrome as a replacement for corticosteroids,
which are recommended within 72 hours of diagnosis in cases of
moderately or severe PCP [30], since the echinocandins do not
have the pan-immunosuppressive effects of corticosteroids and are
virtually non-toxic to mammals.
Like results reported for Aspergillus fumigatus [25], P. murina
underwent profound morphological changes as a result of
echinocandin treatment. The organisms appeared to coalesce into
larger masses with fewer circumscribed boundaries and larger
non-staining bodies. In some cases, the stacked organisms that
lined the alveoli resembled biofilm structures previously observed
in an in vitro Pneumocystis biofilm system [31]. We speculate that
the trophic forms reside in these masses which afford some
protection from the host immune system without activating it.
The echinocandins exhibited a bias of effect on the cyst stage of
P. murina and P. carinii in vivo, which was likely due to the lack of b-
glucan in the trophic stage. Similarly, treatment of C. albicans in
vitro and in vivo with caspofungin resulted in a dramatic bias
towards the filamentous morphotype while in A. fumigatus, the
hyphae, but not the germlings or conidia were targeted.
Concomitant with these selective effects was an ‘‘unmasking’’ or
exposing of b-glucan that is naturally cloaked beneath a layer of
mannan [26,27,28,29]. Such unmasking events led to increased
Dectin-1 mediated inflammatory responses to A. fumigatus hyphae
[29] and C. albicans [32]. Unlike C. albicans or A. fumigatus, the
fluorescent staining patterns or intensities of P. carinii were not
effected by anidulafungin, which is in keeping with previous
studies that showed the direct interaction of cysts with alveolar
macrophages via this Dectin-1, without the need for prior
treatment [33].
Another intriguing finding of these studies was the ability to
prevent moderate to severe infection in mice prophylactically
Figure 5. Pneumocystis pneumonia and survival curves of mice treated prophylactically with anidulafungin and caspofungin. Mice
received prophylactic anidulafungin (green bars) and caspofungin (yellow bars) at doses at the dose regimens indicated on the figure legends.
Trimethoprim-sulfamethoxazole (T/S) was given at the lower prophylactic dose of at 12.5/62.5 mg/kg. Bars indicate log10 mean cyst forms6SD/lung.
Panel A: Log10 mean cyst counts of 1.0 and 0. 1 mg/kg caspofungin and anidulafungin. All treatment regimens were significantly different than
untreated control mice (*P,0.001). Panel B: Log10 mean trophic counts of 1.0 and 0. 1 mg/kg caspofungin and anidulafungin. All treatment regimens
were significantly different than untreated control mice (*P,0.001). Panel C: Survival curves of mice that received 1 mg/kg of anidulafungin and
caspofungin once per week. 1X/week dosing: anidulafungin, 1 mg/kg: P=0.03. Panel D: Survival curves of mice that received 1 mg/kg of
anidulafungin and caspofungin thrice per week. Significance for 3X/week dosing: caspofungin, 1 mg/kg: P=0.002; caspofungin, 0.1 mg/kg: P=0.002.
doi:10.1371/journal.pone.0008524.g005
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infrequently as once per week. These mice had dramatically
reduced cysts and significantly lowered numbers of trophic forms
when compared to untreated controls. Recipient mice treated with
the echinocandins received the same exposure to infected mice as
did the non-echinocandin treated mice who developed robust
infections. This suggests that blocking of b-1,3-D-glucan synthesis
interfered with establishment of a fulminate infection perhaps by
inhibiting cyst formation in the recipient mice. These results
provide some evidence that the cyst is the infectious agent that
transmits the infection and also may be required for efficient
replication in the mammalian hosts. Although the echincandins
have the disadvantage of parenteral administration, the once
weekly regimen offers an alternative to patients that cannot
tolerate standard prophylaxis.
Studies exploiting the ability of anidulafungin treatment to
provide mice with infections comprised almost entirely, if not
entirely of trophic forms provided strong evidence that cysts are
required for transmission, as these mice could not transmit the
infection to immunosuppressed, uninfected mice via the natural,
airborne route. Yet the trophic forms from the treated mice were
viable and caused infection when directly inoculated into
immunosuppressed mouse lungs, although these infections were
generally lower in organism burden than their counterparts. This
Figure 6. b-1,3-D-glucan in the lungs of mice treated prophy-
lactically with echinocandins. b-1,3-D-glucan contents in the lungs
of treated and untreated mice and rats were quantified with the
GLUCATELL
TM kit. Red bar (C/S)=untreated, immunosuppressed mice;
Green bars=anidulafungin; Yellow bars=caspofungin; Pink bar=pro-
phylactic dose of TMP/SMX (12.5/62.5 mg/kg). Dose regimens are
described on the X-axis. (*) The average of the untreated mouse group
was statistically different (P,0.001) from all groups treated prophylac-
tically except anidulafungin 0.1 mg/kg/1x/wk and the TMP/SMX
prophylactically -treated mice. (**)The average of the mice prophylac-
tically treated with anidulafungin 0.1 mg/kg/1x/wk was statistically
different from all of the echinocandin-treated mouse groups (P,0.001)
but not from the TMP/SMX treated or the untreated mice. (
{) The mice
treated prophylactically with TMP/SMX treated were significantly
different from all of the echinocandin-treated mice except for
anidulafungin 0.1 mg/kg/1x/wk and the untreated control group
(P,0.001).
doi:10.1371/journal.pone.0008524.g006
Figure 7. Effects of anidulafungin on b-1,3-D-glucan in P. carinii.
P. carinii from the lungs of immunosuppressed rats were treated with
60 mg/ml anidulafungin for 24 hrs and reacted with a mAB to b-1,3-D-
glucan conjugated to Alexafluor 594. Panel A: Non-anidulafungin
treated P. carinii viewed by phase microsocopy showing a cluster of
trophs (arrow) attached to a cyst; Panel B: the same cluster viewed by
fluorescent microscopy; no trophs were stained by the antibody; Panel
C: Anidulafungin-treated P. carinii viewed by phase contrast microsco-
py; and Panel D: the same cluster under fluorescent excitation. Note the
punctate staining pattern in both samples. All panels magnified
according to the bar in Panel C.
doi:10.1371/journal.pone.0008524.g007
Figure 8. Anidulafungin-treated mice cannot transmit Pneu-
mocystis infection. Panel A: Average cyst counts of mice exposed to
untreated infected mice (Not treated, ‘‘Not Tx’’) or anidulafungin treated
(‘‘Anid Tx’’) mice and immunosuppressed for 2, 4 and 6 wks. ‘‘Controls’’
were non-exposed, immunosuppressed mice (‘‘Cont’’). Panel B: P.
murina mtLSU message was detected by RT-qPCR and expressed as
nuclei/reaction.
doi:10.1371/journal.pone.0008524.g008
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echincandin on trophic viability or due to a longer time period
required to reach higher infection levels without cysts in the
initial population. Nonetheless, these studies provide compelling
evidence that the cyst form of Pneumocystis is required for natural,
airborne transmission. In vivo, the cyst is 5–8 mm which is a
sufficient diameter to permit deposition in the deep airways [34].
In addition, desiccation is known to reduce the size of fungal
spores [35] and desiccation of the cysts by contact with air
during the transmission route would further reduce the size
resulting in even smaller aerosols that could remain airborne
longer, increasing the chances of transmission. The added
advantage of 8 ascospores contained within the cyst would
potentially provide a more rapid establishment of infection and
perhaps contain the mating types necessary to initiate sexual
replication.
The lack of mortality associated with echinocandin treated mice
may have been due to the lack of glucan, which has been shown to
be a pro-inflammatory factor, with detrimental as well as beneficial
immune responses [36,37,38,39]. Previous studies have implicated
b -1,3-D-glucan as a cause of a destructive inflammatory response
that contributes to the disease process in Pneumocystis spp.
pneumonia, however, these studies relied on responses from
isolated alveolar epithelial cells, macrophages, or T-cells
[37,38,40], isolated dendritic cells [39] or by installation of a
glucan-enriched preparation from P. carinii into healthy mice [40].
Our studies extend and enhance the previous studies by showing
that in vivo removal of the specific b -1,3-D-glucan component of
the cyst using echinocandin treatment, reduced the mortality of
the treated animals, even with significant trophic burdens
remaining. The model can now be used to directly investigate
immune responses to the individual stages both in vitro and in
vivo.
Anidulafungin and caspofungin were able to modulate and
regulate the Pneumocystis spp. life cycle. Inhibition of b-1,3-glucan
synthesis lead to an infection that was comprised primarily,
if not all, of trophic forms, which is presumed to be the asexual
phase of the life cycle. Using these compounds, identification of
the genes necessary for asexual vs sexual replication and those
involved in the switch between the 2 phases can now be
identified.
Materials and Methods
All animals were handled in strict accordance with good animal
practice as defined by the University of Cincinnati and VAMC
IACUC and all animal work was approved by the appropriate
committees: UC 06-03-23-01 and VA 06-06-02-01. The animal
husbandry and experimental procedures are consistent with the
recommendations in the Guide for the Care and Use of
Laboratory Animals (the Guide), the Animal Welfare Act
Regulations (AWARs), and the Public Health Service Policy on
Humane Care and Use of Laboratory Animals (PHS Policy). To
safeguard against environmental exposure of P. murina and other
microbes, mice are housed under barrier conditions with
autoclaved food, acidified water, and bedding in sterilized shoebox
cages equipped with sterile microfilter lids [41]. Access is limited to
animal care and technical personnel who are required to wear
sterile caps, gowns, masks, gloves and booties while in the animal
rooms. The animals are observed daily and those that appear
gravely ill or moribund are routinely euthanized so as not to cause
any undue suffering. Animals are euthanized by an overdose of
70% carbon dioxide in a precharged airtight chamber followed by
bilateral pneumothorax, which is an approved euthanasia method
according to the latest report of the AVMA Panel on Euthanasia.
Compounds
Caspofungin (Cancidas–Merck Pharmaceuticals, Rahway, NJ),
Micafungin (Mycamine–Astellas Pharma US), and Anidulafungin
(Eraxis–Pfizer, New York, NY) were all purchased commercially
as a powder. Trimethoprim-sulfamethoxazole (SulfatrimH, Acta-
vis, Baltimore, MD) was purchased as a pediatric oral suspension.
In vivo Mouse Studies
Therapy. Evaluation of anti-Pneumocystis spp. activities was
conducted with an immunosuppressed mouse model of
pneumocystosis infected with P. murina as previously described
[42]. C3H/HeN mice were exposed to previously infected mice
for 2 weeks (a process termed, ‘‘seeding’’, which is the most
‘‘natural’’ method of infection) and begun on an immuno-
suppressive regimen the first day of exposure (4 ug/ml
dexamethasone in drinking water). Mice with moderate P. murina
infections (4–5 weeks post exposure) were randomly divided into
Figure 9. Intranasal inoculation of P. murina from anidulafungin treated mice cause infection and are viable. Panel A: Average log10
cysts in the lungs of immunosuppressed mice intranasally inoculated with anidulafungin treated or non-treated organisms. Not Tx=non-treated;
Anid Tx=anidulafungin treated P. murina. 2-, 4-, 6 wks immunosuppression; Cont=immunosuppressed uninoculated mice. Panel B: RT-qPCR of
immunosuppressed mice inoculated with anidulafungin-treated or non-treated P. murina. Legend as in Panel A. Significant differences between
groups are shown on the figure.
doi:10.1371/journal.pone.0008524.g009
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treatment regimen or vehicle sham (C/S; Control, Steroids). The
echinocandins were dissolved in sterile 0.9% sodium chloride
and were administered by intraperitoneal (ip) injection on a
mg/kg basis once daily for 3 days/week at varying dose levels
and once per week for selected compounds. Trimethoprim-
sulfamethoxazole (T/S) pediatric suspension was administered by
oral gavage at 50 mg–250 mg per dose. The drug treatment
continued for 3 weeks during which time the mice remained on
the immunosuppressive regimen. Mice were examined daily for
any signs of overt toxicity during the treatment phase as previously
described [42].
Prophylaxis. The prophylaxis studies were performed in the
same manner as described above except the mice were treated for
the entire duration of the 7–8 week study with dexamethasone and
echinocandin and exposed to P. murina-infected mice during the
first 2 weeks of immunosuppression. A reduced regimen of 12.5/
62.5 mgTMP-SMX was used as the prophylactic dose, based on
previous studies in rats [43].
Evaluation of efficacy. Efficacy was based on a reduction in
organism burden in treated vs untreated mice determined by
microscopic quantification. The right lung was homogenized and
slides were stained with cresyl echt violet (CEV), which selectively
stains the cyst form of P. murina and a rapid version of the Wright-
Giemsa stain (Leuko-stat, Fisher Scientific) to enumerate trophic
forms [42]. The microscopic counts were log transformed and the
group outcomes were compared by the one way ANOVA followed
by Newman-Keuls multiple comparison post test using INSTAT
v.4 (GraphPad software for Science, San Diego, CA). Significance
was accepted when the P value was ,0.05. The limit of detection
by this enumeration method is 1.75610
4 (log10 4.24/lung).
Survival curves were based on the 21-day treatment period and
were compared using GraphPad Prism v.4. Significance was
accepted when the P value was ,0.05.
Histological evaluation. The left lungs of 5 of the mice
therapeutically treated with 10-, 5- and 1 mg/kg of the 3
echinocandins in each group and 3 from untreated controls were
inflated with a solution of 10% buffered formalin solution and
submitted to the University of Cincinnati Comparative Pathology
Coreforfurtherprocessing.The sectionswerestainedwith Grocott’s
methenamine silver (GMS) which stains fungal cell walls including
those of the cysts of Pneumocystis. All slides were examined in a
blinded manner by a pathologist (RB). Morphological analyses were
conducted using an Olympus BH2 microscope and an Olympus
DP72 digital camera and software system.
Withdrawal of Anidulafungin to Evaluate Return of Cyst
Populations
Two separate studies were conducted using C3H/HeN and
scid/scid mice. P. murina infections were induced in mice as
described above for the therapeutic studies. Mice were then
treated with 1 mg/kg anidulafungin for three weeks after which
the treatment was stopped, but the immunosuppression was
continued. Control mice received no treatment, but the same
length of immunosuppression. Groups of 3–6 mice per group were
sacrificed immediately after stopping the treatment and then at 1,
2, 3, and 4 weeks post cessation. The lungs were processed and
examined microscopically for trophic and cyst forms as described
above. The results from the 2 experiments were averaged and
analyzed using descriptive statistics.
Transmission Studies
To assess the ability of anidulafungin treated P. murina infected
mice to transmit the infection, P. murina- naı ¨ve immunosuppressed
C3H/HeN mice were co-housed (seeded) with anidulafungin-
treated or control, untreated P. murina- infected C3H/HeN mice.
The mice serving as the treated seed mice received anidulafungin
at a dose 1 mg/kg, i.p. 3x per week. This treatment regimen
results in elimination of almost all cyst forms from the lungs of the
treated mice, but similar levels of trophic burdens remain in the
untreated and anidulafungin treated mice (See results). Following
the 3 weeks of anidulafungin treatment, the treated mice were then
used as seed mice and the anidulafungin dosing was continued
during the seeding period of 2 weeks.
One treated or untreated control mouse was co-housed in the
same cage with 4–6 naı ¨ve immunosuppressed mice. To ensure that
all recipient mice were exposed to a similar level of P. murina
during the seeding, the seed mice were rotated between cages
every 2–3 days to account for potential variations in P. murina
infection levels between the seed mice. Following the 2 weeks of
seeding, the control or treated seed mice were removed from the
cages. The seed mice were sacrificed, and the lungs processed to
evaluate the level of P. murina infection and for preparation of
inocula as previously described [42].
The recipient mice were continued on immunosuppression and
sacrificed at 2, 4, and 6 wks post initial exposure. Immunosup-
pressed mice with no experimental exposure to P. murina were also
sacrificed at each time point, as controls.
Quantification by Reverse Transcriptase quantitative
PCR (RT-qPCR). To detect low level infections and to ensure
that the organisms are viable, RT-qPCR was performed and
compared to microscopic counts. At the time of sacrifice the lungs
were flash frozen in liquid nitrogen, ground into a fine powder,
extracted by TriazolH, quantified and stored at 270uC for
subsequent microscopic (cyst enumeration) and quantitation of
the P. murina large subunit ribosomal RNA gene (mtLSU) message
levels [44]. The amount of P. murina large subunit ribosomal RNA
gene (mtLSU) message was quantified using a previously described
TaqMan assay [45]. The threshold cycle for each sample was
identified as the point at which the fluorescence generated by
degradation of the TaqMan probe increased significantly above
the baseline. To convert the threshold cycle data to P. murina
nuclei, a standard curve was generated using cDNA made from
RNA isolated from 10
7 P. murina nuclei. The level of infection of
the samples was estimated using the standard curve. The efficiency
of the standard curve PCR reactions consistently approached
100% in our hands. Importantly, detection of P. murina mtLSU
with this assay has also been shown to correlate with viability of
the organisms [33].
To ensure that high quality RNA was isolated from all samples
and that cDNA synthesis was successful, a SybrGreen incorpora-
tion RT-PCR assay for the mouse vimentin gene mRNA was
performed on all samples. Primers amplify a 109 base pair product
from mouse vimentin mRNA. The fluorescent signal generated by
incorporation of SybrGreen into the double-stranded product was
collected at 86uC for 10 sec during each repeat to determine the
threshold cycle for each sample. The fidelity of the PCR reactions
was confirmed by analysis of the melt curve of the vimentin PCR
product. A single peak with an approximate melting temperature
of 88uC was detected as expected. The efficiency of the vimentin
PCR reactions consistently approached 100% in our hands.
Verification of the viability of the anidulafungin-treated
trophic forms. To evaluate whether the trophic populations
isolated from anidulafungin treated mice were viable and infective,
P. murina isolated from either the treated or non-treated control
seed mice, were used to infect P. murina-naı ¨ve immunosuppressed
mice by intranasal instillation of 10
7nuclei in 50 ul as previously
described [46]. The mice were sacrificed at 2, 4, and 6 weeks post
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microscopic enumeration, as described above.
In vivo Rat Studies
A small pilot study was conducted to ensure that the results in
echinocandin- treated rats were similar to those in mice. 12 8 wk
old CD rats (Charles River, Inc.) were received from the vendor,
and their oral cavities swabbed to detect P. carinii colonization
[47]. All rats were negative for the presence of P. carinii. After 1
week of corticosteroid treatment (20 mg/kg Depo-Medrol/
wk)(Pfizer, New York, NY) all rats were intranasally inoculated
with 2610
7 P. carinii nuclei in 0.1 ml of PBS. Rats were continued
on immunosuppression for 5 weeks after which 6 rats were
administered 5 mg/kg anidulafungin (Eraxis), for an additional 3
weeks while on steroids, while the other 6 received no treatment,
and remained on the suppressive regimen. After the 3 wks, the rats
were sacrificed and cyst and trophic forms were enumerated
microscopically as described for mice.
Measurement of b-1,3-D-Glucan in the Lungs
The b-1,3-D-glucan levels in echinocandin treated and
untreated rodent lungs were measured in the mice from the
prophylaxis study and rats from the therapeutic study (described
above). The same homogenates used for enumeration of b-1,3-D-
glucan-mAb and CEV-stained cysts were used for measurement of
total b-1,3-D-glucan content. The GLUCATELL
TM (Associates of
Cape Cod, Inc.,East Falmouth, MA) endpoint assay was used
according to the vendor’s instructions. Aliquots were resuspended
in 1 ml of 1 M sodium hydroxide and shaken at room temperature
for 1 hour. Samples were prepared as 10-fold dilutions in pyrogen
free water in test tubes certified to be free of glucan (Associates of
Cape Cod). Glucan standards were prepared in the same manner
according to vendor instructions, The (1,3)-ß-D-glucan content
was measured by using a linear regression curve of standards from
25–200 pg/ml. The correlation coefficient for the studies
presented was 0.992, within the acceptable range suggested by
the vendor (.0.980). Glucan content was expressed as pg/ml.
One tail P-value was calculated for the rat studies while ANOVA
was used in the mouse study (GraphPad Instat v.3).
Effects of Anidulafungin Exposure on Fluorescent
Staining with a Monoclonal Antibody (mAb) Directed to
b-1,3-D-Glucan
Cryopreserved, untreated, P. carinii were rapidly thawed in a
37uC water bath, washed with PBS, centrifuged at 10006g, and
suspended in RPMI 1640 supplemented with 5% calf serum with
(treated) or without (control) 60 mg/ml anidulafungin at 10
8 P.
carinii/ml [48]. Each suspension was distributed in wells (3 ml) of a
Corning 6-well plate (Corning NY) and incubated for 24 hr at
37uC, 5% CO2. Wells were harvested from control and treated
wells, transferred to microfuge tubes, centrifuged at 10006g for
2 min, and resuspended in 500 ml PBS with 1%BSA. 50 ml was
removed for the ATP assay and 2.5 ml of 1.0 mg/ml b-1,3-D-
glucan mAb (Biosupplies Australia, Victoria, Australia) was added
and incubated at 37uC for 1 hr. The mAb does not cross react
with 1,4-a-glucan nor (1R3, 1R4)-b-glucan. The preparations
were centrifuged, washed and resuspended in the PBS solution to
which 2.5 ml of Alexafluor 594 conjugate (InVitrogen, Molecular
Probes, Inc.) was added. After incubation for 1 hr at 37uC, the
preparations were washed and resuspended as above and
examined under epifluorescence at excitation of 590 nm and
emission of 617 nm, then photographed using an Olympus DP72-
BSW camera and software system. The use of unfixed, live
organisms is sometimes referred to as ‘‘ex vivo’’ fluorescence (evf)
and is used because it preserves the live cell wall organization as
opposed to cross-linking and other effects induced by fixation [27].
A series of 1:2 dilutions of the washed fluorescent control and
treated P. carini solutions were prepared in PBS. Aliquots of 100 ml
of the series made from control and treated organisms were
distributed in an opaque black 96-well plate (Corning, NY) and
quantified for fluorescent intensity using a FluoroStar Optima
plate reader (BMG Labtechnologies, Durham, NC) with an
excitation filter of 590 nm and emission of 617 nm. Fluorescent
intesity was determined by 20 flashes per well.
Supporting Information
Figure S1 Unusual morphologies of P. murina in the lungs of
mice treated with echinocandins. Grocott’s methenamine silver
(GMS)-stained sections of lungs from mice treated with anidula-
fungin and micafungin: Panel a: 106 magnification of ball-like
structure in a mouse treated with 5 mg/kg anidulafungin. Note
the clearly circumscribed boundaries of this ,70 um structure.
Panel b: Higher magnification of the structure. Panel c: Extension
containing GMS-stained organisms in a mouse treated with 5 mg/
kg micafungin. Panel d: Higher magnification of the tip of the
elongation (1250X). Panel e: Chains of GMS-staining organisms
resembling pseudohyphae in a mouse treated with 5 mg/kg
micafungin. Panel f: Higher magnification of a different chain in
the same mouse treated with 5 mg/kg micafungin. Panel g: An
unusual elongated structure in a mouse treated with 5 mg/kg
micafungin. Magnification bars are included for each micrograph.
Found at: doi:10.1371/journal.pone.0008524.s001 (2.26 MB TIF)
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